Treatment of cholestatic fibrosis by altering gene expression of Cthrc1: Implications for autoimmune and non-autoimmune liver disease

Zhaolian Bian, Qi Miao, Wei Zhong, Haiyan Zhang, Qixia Wang, Yanshen Peng, Xiaoyu Chen, Canjie Guo, Li Shen, Fan Yang, Jie Xu, Dekai Qiu, Jingyuan Fang, Scott Friedman, Ruqi Tang, M. Eric Gershwin, Xiong Ma

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Collagen triple helix repeat containing-1 (Cthrc1) is a documented specific inhibitor of TGF-β signaling. Based on this observation, we developed the hypothesis that knocking in/knocking out the Cthrc1 gene in murine models of cholestasis would alter the natural history of cholestatic fibrosis. To study this thesis, we studied two murine models of fibrosis, first, common bile duct ligation (CBDL) and second, feeding of 3, 5-diethoxy-carbonyl-1, 4-dihydrocollidine (DDC). In both models, we administered well-defined adenoviral vectors that expressed either Cthrc1 or, alternatively, a short hairpin RNA (shRNA)-targeting Cthrc1 either before or after establishment of fibrosis. Importantly, when Cthrc1 gene expression was enhanced, we noted a significant improvement of hepatic fibrosis, both microscopically and by analysis of fibrotic gene expression. In contrast, when Cthrc1 gene expression was deleted, there was a significant exacerbation of fibrosis. To identify the mechanism of action of these significant effects produced by knocking in/knocking out Cthrc gene expression, we thence studied the interaction of Cthrc1 gene expression using hepatic stellate cells (HSCs) and human LX-2 cells. Importantly, we demonstrate that Cthrc1 is induced by TGF-β1 via phospho-Smad3 binding to the promoter with subsequent transcription activation. In addition, we demonstrate that Cthrc1 inhibits TGF-β signaling by accelerating degradation of phospho-Smad3 through a proteosomal pathway. Importantly, the anti-fibrotic effects can be recapitulated with a truncated fragment of Cthrc1. In conclusion, our findings uncover a critical negative feedback regulatory loop in which TGF-β1 induces Cthrc1, which can attenuate fibrosis by accelerating degradation of phospho-Smad3.

Original languageEnglish (US)
Pages (from-to)76-87
Number of pages12
JournalJournal of Autoimmunity
Volume63
DOIs
StatePublished - Sep 1 2015

Keywords

  • Anti-fibrotic treatment
  • Cholestatic liver fibrosis
  • Hepatic fibrosis
  • Hepatic stellate cell
  • TGF-β pathway

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Treatment of cholestatic fibrosis by altering gene expression of Cthrc1: Implications for autoimmune and non-autoimmune liver disease'. Together they form a unique fingerprint.

  • Cite this

    Bian, Z., Miao, Q., Zhong, W., Zhang, H., Wang, Q., Peng, Y., Chen, X., Guo, C., Shen, L., Yang, F., Xu, J., Qiu, D., Fang, J., Friedman, S., Tang, R., Gershwin, M. E., & Ma, X. (2015). Treatment of cholestatic fibrosis by altering gene expression of Cthrc1: Implications for autoimmune and non-autoimmune liver disease. Journal of Autoimmunity, 63, 76-87. https://doi.org/10.1016/j.jaut.2015.07.010